echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Wes sources work with Cogstate to expand the global development and commercialization of digital cognitive assessment technologies

    Wes sources work with Cogstate to expand the global development and commercialization of digital cognitive assessment technologies

    • Last Update: 2021-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    This global licensing agreement is an extension of the existing partnership between the two parties.
    original agreement was implemented in August 2019, in which Aedes aegym obtained exclusive development and commercialization rights in Japan for all cognitive function tests developed by Cogstate, including CBB.
    the two companies plan to continue to advance the development of CBB globally, using CBB as a tool for individuals to self-assess brain function, to help people choose healthy lifestyles and take preventive measures in their daily lives, and as a medical device to assist medical practitioners in making clinical diagnostic decisions.
    CBB is a digital tool developed by Cogstate that performs cognitive function self-testing and uses four tests to assess mental motor function, attention, learning memory, and working memory.
    Cogstate's technology is easy to use, available in more than 70 languages and has been scientifically validated by more than 600 peer-reviewed publications.
    COGTSTATE technology has been widely used in clinical trials, including a number of trials conducted by Wesser.
    In the United States, Europe, Australia, New Zealand and Canada, CBB is used as a "CognigramTM" medical device and has obtained market authorization from regulators in those regions to provide medical personnel with informational results to support clinical testing and assist in the diagnosis of MCI and dementia.
    is currently building a dementia patient platform called "Easyit", which centers on the brain performance self-test tools "NouKNOW" and "Easyit App" (an app designed to promote health action through visualization of brain and physical health data).
    is investigating the possibility of developing medical devices in Japan that combine CBB technology.
    note: There are deletions in the original text
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.